[Pharmacokinetics of ponsinomycin administered in a syrup form in single 400-800 and 1200 mg doses in healthy volunteers].
Ponsinomycin is a new macrolide. Its pharmacokinetics is characterized by an extensive metabolism. Following oral dosing in human, unchanged ponsinomycin is not found in blood, but 3 main metabolites: Mb12, Mb6 and Mb9a can be assayed. Twelve young healthy volunteers received ponsinomycin orally, at doses equal to 400, 800 and 1,200 mg on 3 separate occasions, according to a cross-over design. Metabolites Mb12, Mb6 and Mb9a were measured in plasma by HPLC. The pharmacokinetics of Mb12 was linear in the range of doses administered. A dose-dependent effect leading to a reduction of the apparent elimination rate when dose increased was observed with Mb9a and more importantly with Mb6.
Couet
W
W
Développement de la Pharmacologie Clinique (ADPC), Poitiers.
Girault
J
J
Reigner
B
B
Ingrand
I
I
Bizouard
J
J
Fourtillan
J B
JB
D000284:Administration, Oral; D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology*; D008297:Male; D015644:Miocamycin
D007933:Leucomycins; D015644:Miocamycin
Pharmacocinétique de la ponsinomycine administrée sous forme de sirop en prises uniques aux doses de 400-800 et 1,200 mg chez le volontaire sain.